Bacil Pharma Quarterly Results for Trading Insights
In March 2025, Bacil Pharma (BACPHAR) reported revenue ₹1 Cr and net profit ₹0 Cr. Compare with BACPHAR stock valuation models to assess whether the stock is under or overvalued.
BACPHAR Quarterly Results — Revenue, Profit & EPS Highlights
Bacil Pharma latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Bacil Pharma stock price NSE.
- Revenue of ₹1 Cr in March 2025
- Earnings Per Share of ₹0.64 in March 2025 (+740.0% vs March 2024)
Bacil Pharma Quarterly Results — Revenue, EBITDA, Net Profit & EPS
BACPHAR quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 1 | 0 | 0 | 0 | 0 | - | - |
| Net Profit (₹ Cr) | 0 | 0 | 0 | -4 | 0 | - | - |
| EBITDA (₹ Cr) | 0 | 0 | 0 | -4 | 0 | - | - |
| EPS (₹) | 0.64 | -0.10 | -0.17 | -6.55 | -0.41 | - | - |
| Operating Margin (%) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | - |
BACPHAR Share Price Trend — 1-Year Movement Across Quarterly Results
Bacil Pharma 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore BACPHAR price trends to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
BACPHAR vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Bacil Pharma latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹442,581.33 Cr | 1844.3 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 163.2 |
|
Divis Laboratories
Mar 2026 |
₹179,363.85 Cr | 6797.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 240.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹153,579.77 Cr | 4537.8 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 394.2 |
|
Cipla
Mar 2026 |
₹114,559.46 Cr | 1418.2 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 206.4 |
|
Dr Reddys Laborator…
Mar 2026 |
₹110,089.41 Cr | 1319.0 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 497.7 |
All amounts in ₹ Crores